Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
South Med J ; 86(11): 1269-72, 1993 Nov.
Article in English | MEDLINE | ID: mdl-8235783

ABSTRACT

Angiotensin converting enzyme (ACE) inhibitors have become commonly used medications for hypertension and congestive heart failure. These agents are noted for their low incidence of adverse effects; but in certain cases, these effects can be life-threatening. Severe hyperkalemia is one of the potentially dangerous effects of the ACE inhibitors. While cases of life-threatening hyperkalemia associated with the use of ACE inhibitors have been described previously, in no instance was dialysis required. Herein, we report a case of acute hyperkalemia in a patient with congestive heart failure and renal insufficiency, the resolution of which required hemodialysis. The hyperkalemia in this case occurred without an increase in the patient's azotemia. In addition, the patient did not respond to attempts to effect the intracellular shift of potassium. This suggested that there may have been a defect in internal potassium homeostasis.


Subject(s)
Captopril/adverse effects , Hyperkalemia/chemically induced , Aged , Aged, 80 and over , Humans , Hyperkalemia/therapy , Male , Renal Dialysis
2.
Am J Med Sci ; 304(5): 312-8, 1992 Nov.
Article in English | MEDLINE | ID: mdl-1442873

ABSTRACT

Diuretics were the first effective oral agents for treating hypertension. They have proven to be safe and effective. Recently, they have been scrutinized as possibly being responsible for certain side effects that may increase risk for cardiovascular morbidity and mortality. A careful review of the literature suggests this class of agents warrants continued use as first-line therapy of hypertension, especially in certain demographic groups. However, monitoring of potential baleful effects and a general reduction in dosage are appropriate. Furthermore, selection of other (alternative) agents for monotherapy is advised in certain clinical circumstances.


Subject(s)
Diuretics/therapeutic use , Hypertension/drug therapy , Hemodynamics , Humans , Hypertension/physiopathology , Nephrons/physiology , Nephrons/physiopathology
3.
Clin Nephrol ; 36(5): 258-61, 1991 Nov.
Article in English | MEDLINE | ID: mdl-1752077

ABSTRACT

Calcium carbonate is frequently used in large doses as a phosphorus binder in hemodialysis patients, which often results in hypercalcemia. In most studies in which calcium carbonate is prescribed to control serum phosphorus levels the patients are not given calcitriol. However, calcitriol may be necessary for suppression of parathyroid hormone. The risk of hypercalcemia when calcium supplements are used in conjunction with calcitriol has not previously been examined in detail. We reviewed the charts of 74 hemodialysis patients (119 patient dialysis years) to determine the relationship of serum calcium to calcitriol, calcium therapy, and PTH levels. Twenty-eight patients (38%) were hypercalcemic at some point. Calcitriol therapy significantly increased the risk of hypercalcemia, independently of calcium therapy (p = 0.032). However, patients on a low dose of calcitriol were more than twice as likely to be hypercalcemic than patients on higher doses. Mean PTH levels were lower in the patients on the lower doses of calcitriol, indicating less severe hyperparathyroid disease. We conclude that hypercalcemia is a common complication in hemodialysis patients on calcitriol and calcium carbonate. Whether lowering the dialysate calcium, as suggested by other investigators, will successfully decrease the risk of hypercalcemia without worsening hyperparathyroidism remains to be determined.


Subject(s)
Calcitriol/adverse effects , Calcium Carbonate/adverse effects , Hypercalcemia/chemically induced , Iatrogenic Disease , Renal Dialysis , Adult , Calcitriol/therapeutic use , Calcium Carbonate/therapeutic use , Female , Humans , Hypercalcemia/epidemiology , Hyperparathyroidism, Secondary/drug therapy , Male , Middle Aged , Phosphorus/blood , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...